Welcome to our dedicated page for Rapt Therapeutics SEC filings (Ticker: RAPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The RAPT Therapeutics, Inc. (Nasdaq: RAPT) SEC filings page on Stock Titan provides access to the company’s official reports and disclosures filed with the U.S. Securities and Exchange Commission. As a clinical-stage immunology-based biopharmaceutical company focused on inflammatory and immunological diseases, RAPT uses SEC filings to report financial results, capital-raising activities and other material corporate events.
Investors can review current and historical Form 8-K filings in which RAPT reports items such as quarterly and year-to-date financial results, underwritten public offerings of common stock, and changes to its board of directors and governance arrangements. For example, recent 8-K filings have furnished press releases detailing net losses, research and development and general and administrative expenses, cash and marketable securities balances, and the terms and expected proceeds of a public equity offering intended to fund operations into 2028 based on the company’s stated operating plans.
Beyond 8-Ks, RAPT’s broader SEC reporting (such as Forms 10-Q and 10-K, referenced in its press releases) contains more extensive discussions of risk factors, pipeline programs, clinical trial status and accounting policies. These periodic reports are important for understanding how the company describes its clinical-stage immunology-based business model, including programs like ozureprubart and other early-stage assets, as well as its assessment of capital needs and potential risks.
On Stock Titan, SEC filings are updated in near real time as they are posted to the EDGAR system. AI-powered summaries help explain the key points of lengthy documents, highlighting items such as changes in operating expenses, financing transactions, and material clinical or regulatory disclosures described in attached press releases or narrative sections. Users can quickly scan these summaries before diving into the full text of a filing.
For those tracking executive and director matters, RAPT’s filings also include information on board appointments, committee assignments and compensation policies, as seen in governance-related 8-K disclosures. Together, these documents provide a structured record of how RAPT communicates its financial condition, capital structure and development progress to regulators and the market.
RAPT Therapeutics director Lori Lyons-Williams reported the cash-out of equity awards tied to the company’s acquisition by GSK. On March 3, 2026, multiple director stock options and 4,956 common shares were disposed of pursuant to a tender offer and merger at $58.00 per share, with RSUs and options cancelled and converted into cash under the Merger Agreement.
RAPT Therapeutics director Mary Ann Gray reported dispositions of stock options and shares tied to the company’s acquisition by a GlaxoSmithKline affiliate. On
Under the merger agreement, all outstanding restricted stock units were cancelled and converted into the right to receive cash based on the
RAPT Therapeutics director Michael F. Giordano reported the disposition of equity awards and shares in connection with the company’s acquisition by GlaxoSmithKline. The filing shows multiple Director Stock Options and 4,956 shares of common stock disposed on March 3, 2026, including a disposition pursuant to a tender offer.
Under a Merger Agreement dated January 19, 2026, a GSK subsidiary completed a tender offer to acquire all outstanding RAPT shares for
RAPT Therapeutics director Ashley L. Dombkowski reported disposing of equity awards in connection with the company’s acquisition by a GlaxoSmithKline affiliate. On March 3, 2026, 25,000 director stock options and 4,956 shares of common stock were surrendered to the issuer or purchaser as part of the closing.
Under a previously signed Merger Agreement, a GlaxoSmithKline subsidiary completed a tender offer to acquire all RAPT common shares for $58.00 per share in cash, then merged with RAPT, which became an indirect wholly owned subsidiary. At the merger’s effective time, all outstanding RSUs and eligible stock options were cancelled and converted into the right to receive cash based on the $58.00 offer price.
RAPT Therapeutics’ chief financial officer, Rodney KB Young, reported the cash-out of equity awards tied to the company’s acquisition by GlaxoSmithKline. The filing shows dispositions of several employee stock options back to the issuer and the tender of 3,304 common shares.
Under a merger agreement with GlaxoSmithKline LLC and its affiliates, all RAPT common shares were acquired for
Certain unvested options granted after March 1, 2025 were instead converted into cash-based awards of the GSK parent. These converted awards retain the original vesting conditions but pay out 50% at closing and 50% nine months later, with full acceleration if the holder is involuntarily terminated within that nine-month period.
RAPT Therapeutics chief scientific officer Dirk G. Brockstedt reported dispositions of common stock and employee stock options tied to the company’s acquisition by a GlaxoSmithKline subsidiary. All transactions occurred on
Under a January 19, 2026 Merger Agreement, a tender offer acquired all RAPT common shares at
In-the-money options were cancelled and converted into a right to receive cash equal to the number of option shares multiplied by the excess of the
Wong Brian Russell reported disposition transactions in this Form 4 filing.
RAPT Therapeutics President and CEO Brian Russell Wong reported multiple equity disposals tied to the company’s sale to GlaxoSmithKline. On
Employee stock options were adjusted for a prior 1-for-8 reverse stock split and, at the merger’s effective time, became fully vested. Options with exercise prices below
Certain unvested options granted after
RAPT Therapeutics director Linda Kozick reported the disposition of stock options and common shares in connection with the company’s acquisition by a GlaxoSmithKline affiliate. Multiple “Director Stock Option (right to buy)” awards were disposed of to the issuer on
Under a January 19, 2026 Merger Agreement, a GSK subsidiary completed a tender offer for all RAPT shares at
RAPT Therapeutics director Scott Braunstein reported dispositions of equity tied to the company’s merger with a GlaxoSmithKline affiliate. He surrendered 25,000 director stock options back to the issuer and disposed of 4,956 common shares through a tender offer at $58.00 per share.
The filing explains that, under the Merger Agreement, outstanding restricted stock units and stock options were cancelled at the merger’s effective time and converted into cash based on the $58.00 offer price. These transactions reflect automatic treatment of director awards in connection with RAPT becoming an indirect wholly owned subsidiary of GlaxoSmithKline LLC.